Table 5.
Crude incidences of recurrent VTE in patients with a prior history of VTE
| Risk factor profile | EINSTEIN EXTENSION | EINSTEIN CHOICE | EINSTEIN CHOICE | EINSTEIN EXTENSION and EINSTEIN CHOICE | EINSTEIN EXTENSION | EINSTEIN CHOICE |
|---|---|---|---|---|---|---|
| Rivaroxaban 20 mg (N = 110) | Rivaroxaban 20 mg (N = 198) | Rivaroxaban 10 mg (N = 197) | All rivaroxaban (N = 505) | Placebo (N = 88) | Aspirin (N = 194) | |
| Unprovoked, n/N (%) | 0/54 (0.0) | 3/78 (3.9) | 2/73 (2.8) | 5/205 (2.4) | 2/40 (5.0) | 10/76 (13.2) |
| Provoked by major persistent risk factors, n/N (%) | 0/2 (0.0) | 0/5 (0.0) | 0/7 (0.0) | 0/14 (0.0) | 0 | 1/10 (10.0) |
| Provoked by minor persistent risk factors, n/N (%) | 1/45 (2.2) | 0/93 (0.0) | 0/95 (0.0) | 1/233 (0.4) | 2/42 (4.8) | 6/84 (7.1) |
| Provoked by minor transient risk factors, n/N (%) | 0/7 (0.0) | 0/20 (0.0) | 0/15 (0.0) | 0/42 (0.0) | 0/4 (0.0) | 0/15 (0.0) |
| Provoked by major transient risk factors, n/N (%) | 0/2 (0.0) | 0/2 (0.0) | 0/7 (0.0) | 0/11 (0.0) | 0/2 (0.0) | 0/9 (0.0) |